Myalgic encephalomyelitis (ME), or chronic fatigue syndrome (CFS), is a severe disease affecting more than one million people in the European Union, 80% of whom are women.
New research shows that ‘phenylalanine can be used as a potential biomarker for the diagnosis of CFS’(1) .
This is a blood-based diagnostic test for ME/CFS.
Is the Commission aware of this new research?
Will it make funding available for the research and development of diagnostic tests for ME/CFS?